<DOC>
	<DOC>NCT01467505</DOC>
	<brief_summary>To assess efficacy of telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) for hepatitis C virus (HCV) in a 48-week total treatment duration regimen following liver transplantation.</brief_summary>
	<brief_title>An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Male and female participants between the ages of 18 and 65 years History of orthotopic liver transplantation less than 10 years before the Screening visit but no sooner than 6 months before Day 1 Taking a stable immunosuppressant regimen based on either tacrolimus or cyclosporine without substantial dose changes over the past 3 months Naive to pegylated interferon/ribavirin treatment or experienced with pegylated interferon/ribavirin prior to transplantation with relapse, partial, or null response Documented cirrhosis after liver transplantation Ascites or hepatic encephalopathy within 6 months before Screening Retransplantation for recurrent hepatitis C Treatment for hepatitis C post liver transplantation History within the past 3 months of: rejection within 3 months or greater than (&gt;) 1 rejection within 12 months Current treatment with sirolimus or methylprednisolone. Low dose prednisone use (&lt;5 milligram per day) is permitted History within 3 months of any bacterial infection requiring &gt;1 week of intravenous antibiotics, cytomegalovirus viremia or cytomegalovirus infection with endorgan involvement, fungal disease (except cutaneous and mild oral thrush) History of post transplant lymphoproliferative disease Acceptable laboratory values at Screening as specified in the protocol Positive for human immunodeficiency virus 1/2 (HIV1/2) enzyme immunoassay (EIA) antibody screen or Hepatitis B deoxyribonucleic acid (DNA) or Hepatitis B surface antigen History of hepatocellular carcinoma with high risk of recurrence Any other cause of liver disease deemed clinically significant by the investigator in addition to hepatitis C Autoimmunemediated disease History of acute pancreatitis within 5 years before the Screening visit Prior treatment with an hepatitis C virus (HCV) protease inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>